Home > Insider Trading > Filing (0001839516-22-000004)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819790	Tarsus Pharmaceuticals Inc.	TARS	Biological Products, (No Disgnostic Substances) (2836)	814717861

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1839516	C. Dianne Whitfield	C/O Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618	Chief Human Resources Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-11-29	10,251	$0.00	12,224	No	4	M	Direct
Common Stock	Disposition	2022-11-30	1,182	$16.50	11,042	No	4	S	Direct
Common Stock	Disposition	2022-12-01	1,165	$16.75	9,877	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2022-11-29	10,251	$0.00	10,251	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
23,920			No	4	M	Direct

Footnotes

The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2022.
Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service.